Hims reports revenue miss and surprise loss in Q1
The company reported earnings results on Monday.
Hims & Hers fell in after-hours trading after it reported earnings results that missed Wall Street expectations, giving a glimpse into a rocky quarter for the telehealth company.
For the first three months of 2026, the company reported:
$608 million in revenue, compared to the $616.8 million analysts polled by FactSet were expecting.
A loss per share of $0.40, compared to an expected profit of $0.03. Hims saw its margins shrink this quarter and also faced several one-time costs.
For the full year in 2026, the company expects:
Revenue to hit between $2.8 billion and $3.0 billion, higher than its previous guidance of $2.7 billion to $2.9 billion and in line with the $2.7 billion analysts are penciling in.
Adjusted EBITDA between $275 million and $350 million, higher than its previous forecast of $300 million to $375 million with a lower midpoint than the $317 million analysts are expecting.
The earnings report covers a very dramatic period for the company.
In February, the company rolled out a copy of Novo Nordisk’s Wegovy pill, which it eventually pulled after being sued by the drugmaker and getting scrutiny from regulators. It now partners with Novo to distribute its branded GLP-1s in exchange for dropping its cheaper, higher-margin knockoffs.
Hims spent $33 million on that restructuring, which “consists of inventory write-downs and third-party costs,” the company said. Hims also said it spent $15 million in the quarter on “legal settlement costs.”
Hims has gained a tailwind in recent months after the Food and Drug Administration announced that it would ease restrictions on 12 peptides, which Hims and other consumer health companies are eager to get in on.
.jpg?auto=compress%2Cformat&cs=srgb&fit=max&w=3840)